Health Care·Biotechnology·$10.3B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.27 | N/A | +29.87% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.27 | N/A | +29.87% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed a cautious optimism about their future projects. They acknowledged the competitive landscape but remain focused on their strategic goals.
Management highlighted progress in their pipeline despite the ongoing challenges.
They emphasized their commitment to innovation and long-term growth.
Arrowhead Pharmaceuticals reported a narrower-than-expected loss per share, which was a positive surprise for investors. However, the stock reacted slightly down by 0.17%, indicating that investors may have been looking for more concrete revenue figures or guidance. The lack of revenue data and forward guidance may have contributed to the muted stock reaction.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MICROCHIP TECHNOLOGY
Aug 3, 2015